Table 1.
Data of 16 included studies
| Trial | Species(Na/Nc) | Age(month) | Weigh(g) | Model | Acupuncture(acupoints) | Control intervention | Outcome assessment | Result |
|---|---|---|---|---|---|---|---|---|
| Wang 2004 [11] | SD rats (14/13) SD rats (14/13) |
2~ 3 | 200–250 | 4-VO | EA,20 min/d for 15d, 150HZ, 2 mA, continuous Waveform (GV14, GV20) |
No treatment Nimodipine |
Escape latency Escape latency |
P < 0.01 P > 0.05 |
| Yu 2005 [12] | Wistar rats (15/14) |
NR | 340 ± 40 | EO | manual acupuncture, 30 s/d for 21 d (CV6, CV12, CV17, SP10, ST36) |
Placebo-acupuncture | Escape latency Duration in former platform position Frequency crossing former platform |
P < 0.05 P < 0.05 P < 0.05 |
| Shao 2008 [13] | SD rats (9/8) SD rats (9/8) |
NR | 180–220 | 4-VO | EA,20 min/d for 15 d, 150 HZ, 1–2 mA, Continuous Waveform (BL17, BL20, BL23, GV20) |
No treatment Nimodipine |
Escape latency Escape latency |
P < 0.01 P > 0.05 |
| Wang 2009 [14] | Wistar rats(11/11) | 10 | 300 ± 40 | EO | manual acupuncture, 30 s/d for 21 d (CV6, CV12, CV17, SP10, ST36) | Placebo-acupuncture | Escape latency Duration in former platform position |
P < 0.05 P < 0.01 |
| Wei 2011 [15] | SD rats(10/10) | NR | 200–250 | 2-VO | EA, 20 min/d for 10 d, 50 HZ,1.0 mA, continuous Waveform (GV14, GV20) | No treatment Nimodipine |
Escape latency Frequency crossing former platform Escape latency Frequency crossing former platform |
P < 0.01 P < 0.01 P > 0.01 P > 0.01 |
| Zhao 2011 [16] | Wistar rats(10/10) | 4 | 240 ± 20 | EO | manual acupuncture, 30 s/d for 21 d(CV6, CV12, CV17, SP10, ST36) | Placebo-acupuncture | Escape latency Swimming Speed |
P < 0.01 P > 0.05 |
| Zhu 2011 [17] | SD rats(11/12) | 9 | 460 ± 30 | 2-VO | EA, 20 min/d for 30 d,4HZ, 2.0 mA, continuous waveform (BL23, GV14, GV20) | No treatment | Escape latency | P < 0.01 |
| Zhu 2012 [18] | SD rats(12/10) | 12 | 400 ± 30 | 2-VO | EA, 20 min/d for 30 d,4 HZ, 2.0 mA, continuous waveform (BL23, GV14, GV20) | No treatment | Escape latency | P < 0.05 |
| Zhu 2013 [19] | SD rats(6/6) | NR | 432 ± 30 | 2-VO | EA, 20 min/d for 30 d, 4HZ, continuous waveform (BL23, GV14, GV20) | No treatment | Escape latency | P < 0.05 |
| Yang 2014 CG [20] | Wistar rats (12/12) | NR | 200–250 | 2-VO | manual acupuncture, 360 min/d for 21 d (Frontal region, frontoparietal region and parietal region) | No treatment | Escape latency Swimming distance |
P < 0.05 P < 0.05 |
| Yang 2014 CG [20] | Wistar rats (12/12) | NR | 200–250 | 2-VO | manual acupuncture, 360 min/d for 21 d (Frontal region, frontoparietal region and parietal region) | No treatment | Escape latency Swimming distance |
P < 0.05 P < 0.05 |
| Zhang 2014 [21] | Wistar rats (10/10) | NR | 300–320 | EO | manual acupuncture, 30 s/d for 21 d (CV6, CV12, CV17, SP10, ST36) | Placebo-acupuncture | Escape latency Frequency crossing former platform Duration in former platform position |
P < 0.01 P < 0.01 P < 0.01 |
| Li 2015 [22] | Wistar rats (11/11) | NR | 320–360 | EO | manual acupuncture,30 s/d for 14 d (ST36) | Placebo-acupuncture | Escape latency | P < 0.05 |
| Li 2015 [23] | Wistar rats (10/10) | 2 | 300–320 | EO | manual acupuncture, 30 s/d for 14 d (ST36 | Placebo-acupuncture | Escape latency | P < 0.05 |
| Wang 2015 [24] | Wister rats(10/10) | NR | 200–220 | 2-VO | manual acupuncture, 30 s/d for 21 d (CV6, CV12, CV17, SP10, ST36) | Placebo-acupuncture | Escape latency Swimming speed Duration in former platform position |
P < 0.05 P > 0.05 P < 0.05 |
| Fang 2016 [25] | SD rats(18/18) | 9 | 300–450 | MCAO | EA, 20 min/d for 30 d, 30HZ, 6-15 V, sparse wave (BL23, GV14, GV20) | No treatment | Escape latency | P < 0.05 |
| Li 2016 [26] | Wister rats (14/14) | NR | 270–320 | 2-VO | manual acupuncture, 30 s/d for 14 d (ST36) | Placebo-acupuncture | Escape latency Duration in former platform position Swimming speed |
P < 0.01 P < 0.01 P > 0.05 |
Na number of animals in the acupuncture group, EA electroacupuncture, Nc number of animals in the control group, SD Sprague Dawley, 4-VO 4-vessel occlusion, EO embolic occlusion, 2-VO bilateral common carotid artery occlusion, NR no record, PG positive control group, CG cluster-needling group, MCAO middle cerebral artery occlusion